RxDoctor Payments Data

Tejon Woods

Psychiatric/Mental Health · Redlands, CANPI 1285911214

Payments from drug & device makers

$8,376in general payments, 2019–2025

Across 282 payments — averaging $29.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Johnson & Johnson$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • AbbVie$647
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$539
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$8,26499%
  • Education$1111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,376 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$12,139
Medicare patients
19
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide20$16,920
Aripiprazole40$4,764
Duloxetine Hcl24$690
Buspirone Hcl46$616
Mirtazapine40$490
Bupropion XlBupropion Hcl22$460
Olanzapine17$448
Doxepin Hcl12$396
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine16$395
Fluoxetine Hcl23$299
Sertraline Hcl29$295
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine23$294
Gabapentin11$221
Hydroxyzine Hcl22$211
Bupropion Hcl SrBupropion Hcl13$196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$14$16,92020 claims
Almatica Pharma LLCSertraline Hcl$105$29529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Redlands

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →